{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:36Z","timestamp":1784998956235,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapy-related myeloid neoplasms (t-MNs), including therapy-related myelodysplastic syndrome and therapy-related acute myeloid leukemia, are rare but severe late complications of cytotoxic chemotherapy. This study aimed to identify the occurrence of t-MNs in patients with high-risk gestational trophoblastic neoplasia (GTN) treated at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was conducted in 47 patients with high-risk GTN treated between 1990 and 2023. Clinical data included age, antecedent pregnancy, International Federation of Gynecology and Obstetrics stage, World Health Organization prognostic score, chemotherapy regimen, cumulative etoposide dose, and outcomes. Patients who developed t-MN were compared with those who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 47 patients, 34 (72%) achieved cure without relapse, 6 (13%) achieved cure following relapse, and 7 (15%) did not achieve cure. Four patients (8.5%) developed t-MN after prolonged chemotherapy. The latency from initiation of GTN treatment to t-MN onset ranged from 3 to 5\u00a0years, whereas the interval from the last chemotherapy administration to diagnosis ranged from immediately after treatment completion to 20\u00a0months. All four patients received multi-agent, etoposide-containing regimens with cumulative doses\u2009\u2265\u20096,000\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Cytogenetic and molecular analyses revealed KMT2A (formerly MLL) rearrangements and IDH1\/2 mutations. Despite allogeneic hematopoietic stem cell transplantation, clinical outcomes were unfavorable, and all patients ultimately died of t-MN or associated complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although combination chemotherapy remains essential for high-risk GTN, exposure to high cumulative doses of etoposide confers a risk of secondary t-MNs. Long-term hematologic surveillance and less leukemogenic strategies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03073-4","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:22:13Z","timestamp":1780590133000},"page":"1628-1635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy-related myeloid neoplasms following treatment for high-risk gestational trophoblastic neoplasia: a case series and retrospective analysis"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-9606","authenticated-orcid":false,"given":"Kaoru","family":"Niimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-5091","authenticated-orcid":false,"given":"Eiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4872","authenticated-orcid":false,"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9209-7488","authenticated-orcid":false,"given":"Yuko","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-1825","authenticated-orcid":false,"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"3073_CR1","doi-asserted-by":"publisher","first-page":"16929","DOI":"10.1002\/cam4.6322","volume":"12","author":"A Belhabri","year":"2023","unstructured":"Belhabri A, Heiblig M, Morisset S et al (2023) Clinical outcome of therapy-related acute myeloid leukemia patients: real-life experience in a university hospital and a cancer center in France. Cancer Med 12:16929\u201316944. https:\/\/doi.org\/10.1002\/cam4.6322","journal-title":"Cancer Med"},{"key":"3073_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41379-021-00958-9","volume":"35","author":"YC Liu","year":"2022","unstructured":"Liu YC, Illar GM, Al Amri R et al (2022) Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis. Mod Pathol 35:625\u2013631. https:\/\/doi.org\/10.1038\/s41379-021-00958-9","journal-title":"Mod Pathol"},{"key":"3073_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41375-023-01864-6","volume":"37","author":"D Moreno Berggren","year":"2023","unstructured":"Moreno Berggren D, Garelius H, Willner Hjelm P et al (2023) Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. Leukemia 37:1103\u20131112. https:\/\/doi.org\/10.1038\/s41375-023-01864-6","journal-title":"Leukemia"},{"key":"3073_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","volume":"108","author":"C Nilsson","year":"2023","unstructured":"Nilsson C, Linde F, Huleg\u00e5rdh E et al (2023) Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica 108:1015\u20131025. https:\/\/doi.org\/10.3324\/haematol.2022.281233","journal-title":"Haematologica"},{"key":"3073_CR5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/ijerph9072444","volume":"9","author":"S Ezoe","year":"2012","unstructured":"Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9:2444\u20132453. https:\/\/doi.org\/10.3390\/ijerph9072444","journal-title":"Int J Environ Res Public Health"},{"key":"3073_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1200\/JCO.2014.57.5332","volume":"33","author":"P Savage","year":"2015","unstructured":"Savage P, Cooke R, O\u2019Nions J et al (2015) Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol 33:472\u2013478. https:\/\/doi.org\/10.1200\/JCO.2014.57.5332","journal-title":"J Clin Oncol"},{"key":"3073_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2014.05.004","volume":"134","author":"G Sisti","year":"2014","unstructured":"Sisti G, Kanninen TT, Asciutti S et al (2014) Rate of second primary tumors following diagnosed choriocarcinoma: a SEER analysis (1973\u20132010). Gynecol Oncol 134:90\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2014.05.004","journal-title":"Gynecol Oncol"},{"key":"3073_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tjog.2023.07.019","volume":"62","author":"K Niimi","year":"2023","unstructured":"Niimi K, Yamamoto E, Oda Y et al (2023) A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab. Taiwan J Obstet Gynecol 62:745\u2013748. https:\/\/doi.org\/10.1016\/j.tjog.2023.07.019","journal-title":"Taiwan J Obstet Gynecol"},{"key":"3073_CR9","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","volume":"9","author":"MV Shah","year":"2025","unstructured":"Shah MV, Hung K, Baranwal A et al (2025) Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv 9:3370\u20133380. https:\/\/doi.org\/10.1182\/bloodadvances.2024015238","journal-title":"Blood Adv"},{"key":"3073_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","volume":"5","author":"D Singhal","year":"2024","unstructured":"Singhal D, Kutyna MM, Hahn CN et al (2024) Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment. Blood Cancer Discov 5:400\u2013416. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0103","journal-title":"Blood Cancer Discov"},{"key":"3073_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01571-4","volume":"17","author":"W Xiao","year":"2024","unstructured":"Xiao W, Nardi V, Stein E et al (2024) A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC. J Hematol Oncol 17:56. https:\/\/doi.org\/10.1186\/s13045-024-01571-4","journal-title":"J Hematol Oncol"},{"key":"3073_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","volume":"171","author":"SA Strickland","year":"2022","unstructured":"Strickland SA, Vey N (2022) Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol 171:103607. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103607","journal-title":"Crit Rev Oncol Hematol"},{"key":"3073_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41409-023-01970-0","volume":"58","author":"A Baranwal","year":"2023","unstructured":"Baranwal A, Chhetri R, Yeung D et al (2023) Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant 58:769\u2013776. https:\/\/doi.org\/10.1038\/s41409-023-01970-0","journal-title":"Bone Marrow Transplant"},{"key":"3073_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00416-4","volume":"11","author":"BA Pitel","year":"2021","unstructured":"Pitel BA, Sharma N, Zepeda-Mendoza C et al (2021) Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J 11:18. https:\/\/doi.org\/10.1038\/s41408-021-00416-4","journal-title":"Blood Cancer J"},{"key":"3073_CR15","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF et al (2022) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv 6:2847\u20132853. https:\/\/doi.org\/10.1182\/bloodadvances.2021006239","journal-title":"Blood Adv"},{"key":"3073_CR16","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.1998.16.10.3386","volume":"16","author":"C Kollmannsberger","year":"1998","unstructured":"Kollmannsberger C, Beyer J, Droz JP et al (1998) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16:3386\u20133391. https:\/\/doi.org\/10.1200\/JCO.1998.16.10.3386","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03073-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:42Z","timestamp":1784997342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03073-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3073"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03073-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Nagoya University Graduate School of Medicine (approval number: 2019-0106).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent for publication was waived by the institutional review board because of the retrospective study design and the use of anonymized clinical data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}